53.00 0.00 (0.00%)
After hours: 5:47PM EDT
|Bid||52.75 x 200|
|Ask||53.45 x 200|
|Day's range||52.85 - 54.70|
|52-week range||24.02 - 68.05|
|PE ratio (TTM)||N/A|
|Earnings date||30 Apr 2018 - 4 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||73.36|
The South San Francisco, California-based company said it had a loss of 94 cents per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
There are only two drugs approved for the rare disease, sickle cell anemia, but African American patients are wary of participating in clinical trials.
Bagging the first breakthrough therapy designation for a sickle cell disease modifying treatment boosted confidence last month.
Danish drugmaker Novo Nordisk (NOVOb.CO) will continue to hunt for promising assets to refill its blood products business, after losing out to Sanofi (SASY.PA) in a $4.8 billion (3.41 billion pounds) fight for Belgian biotech company Ablynx (ABLX.BR). "We are currently active on a couple of initiatives that hopefully will succeed and enable us to bolt activities on to our biopharma franchise in 2018," Chief Financial Officer Jesper Brandgaard told Reuters. France's Sanofi won Ablynx and its prized experimental bleeding disorder drug caplacizumab with a 50 percent-higher bid than an previously rejected offer from Novo Nordisk.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously received European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of SCD.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck & Co. Inc. “Wendy is an accomplished biopharmaceutical executive with a proven track record in building and leading organizations, and has significant expertise in pre- and post-launch strategy and marketing of new therapies,” said Ted W. Love, M.D., president and chief executive officer of GBT.
More than 50 years after the cause of sickle-cell disease was discovered, a dozen treatments for the painful and life-shortening inherited condition offer hope for long-overlooked patients.
A Relative Strength Rating upgrade for Global Blood Therapeutic shows improving technical performance.